Genmab A/S Unveils A New Antibody Technology Platform: HexaBody

Copenhagen, Denmark; December 17, 2012 – Genmab A/S (OMX: GEN) announced today the addition of a new proprietary technology, the HexaBody™ platform, to its suite of next generation antibody technologies. The HexaBody platform is a novel technology that allows the creation of differentiated antibody therapeutics by enhancing the natural target killing abilities of antibodies in a fundamentally new way. The HexaBody platform will be used to create novel differentiated antibody therapeutics, to improve the efficacy of existing antibody products, and to potentially repurpose drug candidates that were unsuccessful in previous clinical trials due to lack of potency.